Lexicon Pharmaceuticals reported $5.49M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Abbott USD 13.01B 423M Sep/2026
Acadia Pharmaceuticals USD 342M 34.04M Sep/2026
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Eli Lilly USD 24.4B 1.43B Sep/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Illumina USD 1.17B 10M Sep/2026
Insmed USD 524.42M 98.93M Sep/2026
Ironwood Pharmaceuticals USD 113.04M 6.53M Jun/2026
J&J USD 25.4B 89M Sep/2026
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
MacroGenics USD 32.83M 12.03M Jun/2026
MannKind USD 101.9M 7.47M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Moderna USD 1.31M 98.69M Sep/2026
Novartis USD 14.52B 112M Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Thermo Fisher Scientific USD 12.14B 147M Sep/2026
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
United Therapeutics USD 832.5M 49.2M Sep/2026
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024